Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21794
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSilagy, Andrew W-
dc.contributor.authorFlynn, Jessica-
dc.contributor.authorMano, Roy-
dc.contributor.authorBlum, Kyle A-
dc.contributor.authorMarcon, Julian-
dc.contributor.authorDiNatale, Renzo G-
dc.contributor.authorSanchez, Alejandro-
dc.contributor.authorCarlo, Maria I-
dc.contributor.authorMotzer, Robert J-
dc.contributor.authorColeman, Jonathan A-
dc.contributor.authorRusso, Paul-
dc.contributor.authorOstrovnaya, Irina-
dc.contributor.authorChen, Yingbei B-
dc.contributor.authorAri Hakimi, A-
dc.date2019-09-12-
dc.date.accessioned2019-09-23T04:43:01Z-
dc.date.available2019-09-23T04:43:01Z-
dc.date.issued2019-11-
dc.identifier.citationUrologic Oncology 2019; 37(11): 811.e9-811.e16en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21794-
dc.description.abstractTo report the overall survival (OS) outcomes of patients with nonclear cell renal cell carcinoma (nccRCC) treated at our institution with a cytoreductive nephrectomy (CN) and better understand the clinical and pathological characteristics of the patients that respond best. We queried our prospectively maintained database for patients who underwent CN for nccRCC between 1989 and 2018. Histology was reviewed by an expert genitourinary pathologist, and nccRCC tumors were subdivided into papillary, unclassified, chromophobe, and other histology. Baseline clinicopathology, treatments, and survival outcomes were recorded. Preoperative hematological parameters including the neutrophil-to-lymphocyte ratio (NLR) were analyzed. Significant univariate predictors of OS were tested in a multivariate model. There were 100 nccRCC patients treated with CN. Median age was 61 years (IQR: 48-69) and 65% were male. There were 79 patient deaths with a median OS of 13.7 months (10.8-27.2). Estimated 2- and 5-year survival was 40.1% and 12.2%, respectively. Median follow-up of survivors was 13 months (IQR: 3-30). On multivariate analysis, increasing NLR (hazard ratio [HR] 1.27; 95% confidence interval [CI] 1.14-1.40, P < 0.001) and sarcomatoid features (HR 2.18; 95% CI 1.19-3.97, P = 0.014) conferred worse OS and the presence of papillary features were a favorable prognostic feature (HR 0.37; 95% CI 0.21-0.65, P < 0.001). OS outcomes in patients with nccRCC who underwent a CN are consistently modest throughout the study period. Patients with papillary features and a lower preoperative NLR may be better candidates for a CN.en
dc.language.isoeng-
dc.subjectCytoreductive nephrectomyen
dc.subjectKidneyen
dc.subjectNonclear cell histologyen
dc.subjectPrognosisen
dc.subjectRenal cell carcinomaen
dc.titleClinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleUrologic Oncologyen
dc.identifier.affiliationUrology Service, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationEpidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.affiliationDepartment of Urology, University Hospital of Munich, Munich, Germanyen
dc.identifier.affiliationDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.affiliationDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.doi10.1016/j.urolonc.2019.07.011en
dc.type.contentTexten
dc.identifier.pubmedid31521530-
dc.type.austinJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.